Able Labs Awaits Bankruptcy Court Approval For Sale Of Assets To Aurobindo
This article was originally published in The Pink Sheet Daily
Executive Summary
Trenton, N.J. federal bankruptcy court judge will hear argument on Oct. 19; the deal is contingent upon several items.
You may also be interested in...
FDA Rejects Able Labs’ Plan To Return Products To Market
Able plans to sell its business and assets rather than pursue full resubmission of its ANDAs.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.